Ether

Ether

SCHEMBL38599

CCCCCCCCCCCCCCOC(=O)CC.CCOCC

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.84
RAD52 P43351 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
DGKA P23743 1/20 0.53
FAAH O00519 2/20 0.53
HTR2C P28335 1/20 0.51
EPHX1 P07099 1/20 0.50
DNM1 Q05193 1/20 0.49
TSHR P16473 3/20 0.48
HTT P42858 1/20 0.47
CES2 O00748 1/20 0.47
PRSS1 P07477 1/20 0.46
PRSS2 P07478 1/20 0.46
PRSS3 P35030 1/20 0.46
HCAR2 Q8TDS4 1/20 0.46
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ether SCHEMBL2254830 0.92 NAAA (0.71) NAAARAD52NPSR1DGKAFAAH
SCHEMBL545172 0.92 NAAA (1.00) NAAARAD52NPSR1DGKAFAAH
SCHEMBL1471551 0.92 NAAA (1.00) NAAARAD52NPSR1DGKAFAAH
SCHEMBL1056018 0.92 NAAA (1.00) NAAARAD52NPSR1DGKAFAAH
SCHEMBL21044637 0.92 NAAA (1.00) NAAARAD52NPSR1DGKAFAAH
SCHEMBL112452 0.92 NAAA (1.00) NAAARAD52NPSR1DGKAFAAH
SCHEMBL127979 0.92 NAAA (1.00) NAAARAD52NPSR1DGKAFAAH
SCHEMBL9335976 0.92 NAAA (1.00) NAAARAD52NPSR1DGKAFAAH
SCHEMBL5436011 0.92 NAAA (1.00) NAAARAD52NPSR1DGKAFAAH
SCHEMBL21044673 0.92 NAAA (1.00) NAAARAD52NPSR1DGKAFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1606 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230225987-A1 TOPICAL PHARMACEUTICAL COMPOSITIONS Dermavant Sciences GmbH (CH) 2023-07-20 US claimed
CN-116139029-A Water-in-oil type cool itching-relieving ointment and preparation method thereof 广州翀潇生物科技有限公司 2023-05-23 CN claimed
EP-4171529-A1 TOPICAL PHARMACEUTICAL COMPOSITIONS Dermavant Sciences GmbH (CH) 2023-05-03 EP claimed
WO-2021262917-A1 TOPICAL PHARMACEUTICAL COMPOSITIONS Dermavant Sciences GmbH (CH) 2021-12-30 WO claimed
EP-3820448-A2 TOPICAL DETOMIDINE FORMULATIONS Clexio Biosciences Ltd. (IL) 2021-05-19 EP claimed
US-20210137830-A1 TOPICAL DETOMIDINE FORMULATIONS CLEXIO BIOSCIENCES LTD. (IL) 2021-05-13 US claimed
EP-3496703-B1 MOXIDECTIN TOPICAL LIQUID FORMULATIONS NORBROOK LAB LTD (GB) 2021-05-12 EP claimed
US-10675240-B2 Transdermal cannabinoid formulations MM TECHNOLOGY HOLDINGS, LLC (US) 2020-06-09 US claimed
WO-2020067968-A1 NEW COMPOSITIONS COMPRISING CATECHIN POLYPHENOLS FARMETT LÄKEMEDEL AB (SE) 2020-04-02 WO claimed
WO-2020012415-A2 TOPICAL DETOMIDINE FORMULATIONS CLEXIO BIOSCIENCES LTD. (IL) 2020-01-16 WO claimed
US-6087393-A PREVENTING FROM OXIDATION BY DISPERSING 1-ASCORBIC ACID IN A MIXED GLYCOL CARRIER INCLUDING PROPYLENE GLYCOL, BUTYLENE GLYCOL, AND A STABILIZER IGEN, INC. (US) 2000-07-11 US claimed
EP-0778765-A4 COSMETIC MAKE-UP COMPOSITIONS PROCTER & GAMBLE (US) 2000-04-19 EP claimed
US-6013269-A OIL-IN-WATER EMULSION COMPRISING VOLATILE SILICONE OIL AND/OR VOLATILE HYDROCARBON OIL, NON-VOLATILE OIL, PIGMENT AND ORGANIC AMPHIPHILIC MATERIAL CAPABLE OF FORMING SMECTIC LYOTROPIC LIQUID CRYSTALS IN PRODUCT OR ON THE SKIN THE PROCTER & GAMBLE COMPANY (US) 2000-01-11 US claimed
EP-0778765-A1 COSMETIC MAKE-UP COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1997-06-18 EP claimed
EP-0432494-B1 Pour-on formulations effective for the control of internal and external parasites of homothermic animals AMERICAN CYANAMID CO (US) 1997-02-05 EP claimed
WO-1996011665-A1 COSMETIC MAKE-UP COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1996-04-25 WO claimed
EP-0432494-A2 Pour-on formulations effective for the control of internal and external parasites of homothermic animals AMERICAN CYANAMID COMPANY (US) 1991-06-19 EP claimed
US-4889845-A POLYDIMETHYLSILOXANE MIXTURE; STORAGE STABILITY; E-TYPE PROSTAGLANDINS AMERICAN CYANAMID COMPANY (US) 1989-12-26 US claimed
EP-0249193-A2 Vehicle for topical application of pharmaceuticals AMERICAN CYANAMID COMPANY (US) 1987-12-16 EP claimed
EP-0249194-A2 Topical prostaglandin formulations AMERICAN CYANAMID COMPANY (US) 1987-12-16 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10675240-B2 Transdermal cannabinoid formulations TNNC1, CNR2, TNNT2 NAAA 781/4885RAD52 3867/4885NPSR1 1185/4885
US-20230225987-A1 TOPICAL PHARMACEUTICAL COMPOSITIONS TSLP, SQLE, DHCR7 NAAA 4128/4885RAD52 3738/4885NPSR1 3191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.